

1 **Trends in demographic and clinical characteristics of patients enrolled in HIV care and subsequent**
2 **Antiretroviral Therapy initiation in the Central Africa International epidemiology Database to**
3 **Evaluate AIDS (CA-IeDEA) Adult Cohort 2004-2018.**
4
5
6

7 Adebola A. Adedimeji¹, Donald R. Hoover², Qihu Shi³, Hae-Young Kim³, Ellen Brazier⁴, Jonathan Ross⁵,
8 Gad Murenzi⁶, Christella Twizere, Patricia Lelo⁸, Dominique Nsonde⁹, Rogers Ajeh¹⁰, Anastase Dzudie¹⁰,
9 Denis Nash⁴, Marcel Yotebieng⁵, Kathryn M. Anastos^{1, 5} for the Central Africa IeDEA Consortium
10

11 ¹*Department of Epidemiology and Population Health, Albert Einstein College of Medicine/Montefiore*
12 *Medical Center, Bronx, NY*

13 ²*Department of Statistics, Rutgers University, Piscataway, NJ*

14 ³*Department of Public Health, School of Health Sciences and Practice, New York Medical College,*
15 *Valhalla, NY USA*

16 ⁴*School of Public Health, City University of New York, New York, NY*

17 ⁵*Division of General Internal Medicine, Montefiore Medical Center, Bronx, NY*

18 ⁶*Division of Clinical Education, Rwanda Military Hospital, Kanombe, Kigali, Rwanda*

19 ⁷*Centre National de Reference en Matière de VIH/SIDA, Burundi*

20 ⁸*Pediatric Hospital Kalembe Lembe, Lingwala, Kinshasa, Democratic Republic of Congo*

21 ⁹*CTA Brazzaville, Republic of Congo*

22 ¹⁰*Clinical Research Education, Networking and Consultancy, Yaounde, Cameroon*
23
24

25 Corresponding author:

26 **Adebola A. Adedimeji, Ph.D**

27 Van Etten 3A2F, 1225 Morris Park Avenue

28 Bronx, NY 10461

29 Email: adebola.adedimeji@einsteinmed.org
30
31

1 **Abstract**

2
3 **Background**

4 The Central Africa International epidemiology Database to Evaluate AIDS (CA-leDEA) is a prospective
5 study investigating impact, progression and long-term outcomes of HIV/AIDS among people living with
6 HIV (PLWH) in Burundi, Cameroon, Democratic Republic of Congo (DRC), Republic of Congo (ROC) and
7 Rwanda. We described trends in baseline demographic, clinical and immunological characteristics of
8 patients aged >15 years entering into HIV care in the participating CA-leDEA site and subsequent ART
9 initiation.

10
11 **Materials and Methods**

12 Information on socio-demographic characteristics, height, weight, body mass index (BMI), CD4 cell
13 count, WHO staging and ART status at entry into care from 2004 to 2018 were extracted from clinic
14 records of patients aged >15 years enrolling in HIV care at participating clinics in Burundi, Cameroon,
15 DRC, ROC and Rwanda. We assessed trends in patient characteristics at enrollment in HIV care and ART
16 initiation at the participating site and calculated proportions, means and medians (interquartile ranges)
17 for the main variables of interest.

18
19 **Results**

20 Among 69,176 participants in the CA-leDEA cohort, 39% were from Rwanda, 24% from ROC, 18%
21 from Cameroon, 14% from Burundi and 5% from DRC. More women (66%) than men were enrolled in
22 care and subsequently initiated ART. Women were also younger (32 years) than men (38 years) ($p=$
23 <0.001) when they enrolled in care or subsequently initiated ART at the participating site. Trends over
24 time show increases in median CD4 cell count of 190 cells/uL in 2004 to 334 cells/uL in 2018 at
25 enrollment. Among those with complete data on CD4 counts (60%), women had higher median CD4 cell
26 count at care entry in the CA-leDEA site (299 cells/uL) versus men (249 cells/uL; $p= < 0.001$). Trends in
27 proportion of patients using ART show an increase from 16% in 2004 to 75% in 2018 among those
28 initiating ART for the first time after entry into care in the participating site. As expected, median CD4
29 generally increased after ART initiation ($p= <0.001$).

30
31 **Conclusion**

32 Trends from 2004-2018 in the characteristics of patients participating in the CA-leDEA cohort highlight
33 improvements over time at entry into care and subsequent ART in all participating sites.

1 **Introduction**

2 Globally, over 37.9 million people aged >15 years are living with HIV of whom 24.5 million were
3 estimated to be accessing antiretroviral therapy (ART).¹ Expanded access to ART contributed to
4 improved quality of life and declines in AIDS-related mortality in people living with HIV (PLWH). To
5 consolidate these gains and end the threat of HIV to global public health, the Joint United Nations
6 Program on AIDS (UNAIDS) recommended the “90-90-90” strategy to ensure 90% of PLWH are
7 diagnosed and know their status, 90% of those diagnosed are initiated on ART and 90% of those
8 initiating ART attain viral suppression. To facilitate the attainment of these global targets, the World
9 Health Organization (WHO) put out the “Treat All” guidelines, which recommended immediate ART
10 initiation for all persons diagnosed with HIV regardless of CD4 or viral load.²

11
12 Despite expanded ART access, sub-Saharan Africa (SSA) is still disproportionately burdened by HIV. For
13 instance in 2018, 73% of all new HIV infections diagnosed globally were in the region.³ In most of SSA,
14 progress towards the 90-90-90 targets is uneven with many countries in East and Southern Africa
15 making remarkable progress compared with those in West and Central Africa.^{4,5} Whereas, the 25
16 countries in West and Central Africa comprised only 6% of the world’s population, they accounted for
17 18% of global HIV burden.⁶ The UNAIDS estimated that 4.7 million people living with HIV in West and
18 Central Africa lack access to treatment, a sharp contrast with treatment coverage in East and Southern
19 Africa regions.⁶ These discrepancies led to a regional catch up plan to accelerate progress in West and
20 Central Africa, but this has not translated into meaningful gains in scaling up access for millions of PLWH
21 in the region.⁶

22
23 The lack of progress reflects disparities in access to care for many PLWH in Central Africa who continue
24 to experience late diagnosis, non-linkage to care and poor HIV outcomes.^{1,2,3,4,5,6,7} Social and structural
25 instability, especially stigma, weak health systems, civil unrest and other contextual factors impeded
26 access to HIV care and progress towards universal targets.⁵⁻⁸ To address gaps in access to care for PLWH
27 in Central Africa, it is critical to understand the characteristics of PLWH enrolling in care at given sites
28 and subsequently initiating ART. Additionally, knowledge of trends in demographic, immunological and
29 clinical characteristics among PLWH enrolled in care can highlight challenges in implementing effective
30 strategies to facilitate early diagnosis and linkage to care for PLWH in these countries.

31

1 The Central Africa International epidemiology Database to Evaluate AIDS (CA-IeDEA) research
2 consortium was established with funding from the United States National Institutes of Health to be a
3 resource to investigate the impact, progression and long-term outcomes of the HIV/AIDS epidemic in
4 Central Africa and answer epidemiologic research questions that cannot be answered by separate
5 individual cohorts. The CA-IeDEA routinely collects socio-demographic, clinical and immunologic data
6 from patients enrolled in HIV care at participating treatment sites in Burundi, Cameroon, Democratic
7 Republic of Congo, Republic of Congo and Rwanda. These data provide insights on trends in
8 sociodemographic, clinical and immunological characteristics of adult patients entering HIV care in the
9 given site and subsequently initiating ART in the participating countries. The objective of this study was
10 to examine these trends in sociodemographic, clinical and immunological characteristics of adult
11 patients aged >15 years entering care in the current site and subsequently initiating ART in CA-IeDEA
12 regional cohort from 2004-2018 with the goal of describing trends in these characteristics over time.
13

14 **Methods**

15 *Study Settings*

16 The Central Africa IeDEA (CA-IeDEA) is one of the 7 regional cohorts within the global IeDEA consortium
17 [<https://www.iedea.org/>], with other cohorts in East Africa, Southern Africa, West Africa, North
18 America, the Caribbean and Central/South America and Asia-Pacific regions. The overall IeDEA cohort,
19 which has been previously described⁹ consists of 1.7 million PLWH of which 1.4 million in SSA are on
20 ART.
21

22 The CA-IeDEA cohort currently comprises 19 active sites in Burundi, Cameroon, Democratic Republic of
23 Congo (DRC), Republic of Congo (ROC), and Rwanda, and one historical site in DRC that contributed
24 patient data to the cohort until mid 2013. The 19 active sites are predominantly public sector health
25 facilities, including tertiary-level university teaching hospitals and primary level health centers. All the
26 sites are located in urban or peri-urban settings. Details of CA-IeDEA sites have been previously
27 described.⁹ Patients ever enrolling in HIV care at these participating sites are prospectively included in
28 the CA-IeDEA cohort. Data from routine patient care are regularly extracted from patient records and
29 electronic medical records and harmonized into a regional dataset for use in country-level and regional
30 analyses. As of July 2018, there were approximately 70,000 patients in the CA-IeDEA database.
31
32

1 *Study Design and population*

2 This analysis included all adult patients aged >15 years enrolled for HIV care in the CA-IeDEA cohort at
3 participating sites in Burundi, Cameroon, Democratic Republic of Congo, Republic of Congo and Rwanda.
4 Data obtained during routine patient care in each country are extracted from an electronic data
5 collection and storage system in each country, for example, the Open Medical Records System (in
6 Rwanda), SANTIA (in ROC), SIDA (in Burundi) and RedCap (in Cameroon and DRC) ¹⁰ as mandated by the
7 local health authority in each country. These data are then uploaded to a central data server at the CA-
8 IeDEA data center in New York where they undergo cleaning and harmonization prior to analysis.

9

10 *Ethical Approval*

11 Ethical approval for the study was granted by the Albert Einstein College of Medicine Institutional
12 Review Board in New York, and the relevant ethics review boards in Rwanda (Rwanda National Health
13 Research Committee and the National Ethics Committee), Burundi (Comite National d’Ethique),
14 Cameroon (Comite National D’Ethique la Recherche en la Sante Humaine- CNERSH) DRC (Ministere de
15 l’Enseignement Superieur et Universitaire, University de Kinshasa Ecole de Sante Publique) and in the
16 Republic of Congo (Comite d’Ethique De La Recherche En Sciences De La Sante (CERRSSA). Data for the
17 Central Africa International Epidemiology to Evaluate AIDS (CA-IeDEA) is available upon request.

18

19 *Measures*

20 The following socio-demographic characteristics were assessed at entry into care at the participating CA-
21 IeDEA site: age, gender, and marital status, reported pregnancy among women and route of entry into
22 HIV care in the participating site such as voluntary counseling and testing (VCT), prevention of mother-
23 to-child transmission (PMTCT), Tuberculosis (TB) clinic or In-patient care. Clinical and immunological
24 characteristics assessed at entry into HIV care at the participating CA-IeDEA site included weight, height,
25 BMI, CD4 cell count, WHO stage at enrollment and ART usage. ART usage prior to enrollment was
26 defined as ART use >30 days before entering care in the participating site. ART use immediately after
27 entering HIV care at the participating site was defined as ART initiation starting ≤30 days before
28 enrollment to 30 days after enrollment. We considered CD4 cell count measures at enrollment defined
29 as the closest CD4 measure available at enrollment date up to 3 months and 30 days prior to enrollment
30 date. CD4 cell count measure at ART initiation was defined as first CD4 measure available 30 days and up
31 to 3 months after ART initiation date among patients who initiated ART use after enrollment.

32

1 *Statistical Analysis*

2 For this analysis, we calculated proportions, means (standard deviations) and medians (interquartile
3 ranges) for the main variables of interest. We ultimately categorized all continuous variables as shown in
4 the Tables and used Chi-Square tests to make comparison of all variables between groups. We also
5 calculated the same data summaries by calendar year of enrollment into HIV care at the CA-leDEA
6 participating site and by country.

7

8 **Results**

9 *Demographic and clinical profile of all adults at enrollment into care*

10 Table 1 presents the socio-demographic and clinical profile of 69,176 patients entering HIV care in the
11 CA-leDEA cohort in all the five participating countries. The largest proportion of patients (39%) was in
12 Rwanda and the smallest proportion (5%) was in the DRC. There were almost twice as many women
13 (66%) as men enrolled in the participating sites. Most patients reported being married (28%) or single
14 (23%). The median age at enrollment in the participating CA-leDEA sites was 35 years (IQR: 28,42).
15 Women were generally younger (33 years; IQR: 27, 40) than men (38 years; IQR: 32, 45) at enrollment in
16 the participating clinics. The largest proportion of patients enrolled in HIV care at the participating site
17 through voluntary counseling and testing (VCT) clinics (31%) and prevention of mother-to-child (PMTCT)
18 clinics (9%).

19

20 The median weight, height and BMI for patients at entry into HIV care at participating clinics was 57 kg
21 (IQR: 50,65); 163cm (IQR: 158,169) and 21.63 kg/m² (IQR:19.27,24.38) respectively. Median CD4 at entry
22 into care at the participating site was 282 cells/uL (IQR:139, 476) among those for whom the CD4 cell
23 count measure was available. Women enrolled in care at the participating site with higher CD4 count
24 (299 cells/uL, IQR: 151, 501) than men (249 cells/uL; IQR: 119, 427). About half of patients (49.9%)
25 enrolled in care with WHO Stage I or Stage II disease. Slightly higher proportion of men (24%) enrolled in
26 care with advanced HIV disease (WHO Stage III and Stage IV) than women (20%).

27

28 About 46% of patients who enrolled in care at the participating sites did not use any antiretroviral
29 therapy (ART) up to 3 months post enrollment; 11% initiated ART prior to (> 30 days) enrollment in HIV
30 care at the participating site, and 42% initiated ART immediately after enrollment in HIV care at the
31 participating site. The proportions of those who initiated ART before enrollment in HIV care and after
32 enrollment at the participating sites were similar among men and women.

1 **Table 1: Demographic and clinical characteristics of all adult patients at enrollment into care by sex**

Variable	Code	Total	Women	Men	P-value
Adult		69176	45933 (66.4)	23243 (33.6)	
Pregnant			2869 (6.2)		
Age (yrs) median (IRQ)	Median (IQR)	35(28,42)	33(27,40)	38(32,45)	<0.001
	15-24	8894 (12.9)	7291 (15.9)	1603 (6.9)	<0.001
	25-34	25623 (37.0)	19088 (41.6)	6535 (28.1)	
	35-44	22031 (31.8)	13113 (28.5)	8918 (38.4)	
	45+	12628 (18.3)	6441 (14.0)	6187 (26.6)	
Point of entry into care	PMTCT	6530 (9.4)	5623 (12.2)	907 (3.9)	<0.001
	TB	38 (0.1)	27 (0.1)	11 (0.0)	
	VCT	21285 (30.8)	12372 (26.9)	8913 (38.3)	
	Inpatient	1009 (1.5)	524 (1.1)	485 (2.1)	
	Other	6177 (8.9)	3904 (8.5)	2273 (9.8)	
	Unknown	34137 (49.3)	23483 (51.1)	10654 (45.8)	
Marital status	Single	15894 (23.0)	10911 (23.8)	4983 (21.4)	<0.001
	Married/in union	19345 (28.0)	10735 (23.4)	8610 (37.0)	
	Living with partner	3413 (4.9)	2372 (5.2)	1041 (4.5)	
	Divorced	3153 (4.6)	2326 (5.1)	827 (3.6)	
	Widowed	5073 (7.3)	4299 (9.4)	774 (3.3)	
	Unknow/Missing	22298 (32.2)	15290 (33.3)	7008 (30.2)	
Weight for adults, Kg	Median (IQR)	57(50,65)	56(49,64)	59(53,67)	<0.001
	Missing n (%)	20702(29.9)	13901(30.3)	6801(29.3)	
Height for adults, Cm	Median (IQR)	163(158,169)	160(155,165)	170(165,175)	<0.001
	Missing n (%)	20555(29.7)	13551(29.5)	7004(30.1)	
BMI	Median (IQR)	21.63(19.27,24.38)	22.07(19.53,24.98)	20.94(18.93,23.31)	<0.001
	Missing n (%)	31156(45.0)	20702(45.1)	10454(45.0)	
CD4 count (cells/uL)	Median (IQR)	282(139,476)	299(151,501)	249(119,427)	<0.001
	<100	7500 (10.8)	4610 (10.0)	2890 (12.4)	<0.001
	100-199	7513 (10.9)	4846 (10.6)	2667 (11.5)	
	200-349	10093 (14.6)	6739 (14.7)	3354 (14.4)	
	>350	16456 (23.8)	11811 (25.7)	4645 (20.0)	
	Missing n (%)	27614 (39.9)	17927 (39.0)	9687 (41.7)	
WHO Stage at enrollment	Stage I	21004 (30.4)	14247 (31.0)	6757 (29.1)	<0.001
	Stage II	12961 (18.7)	8659 (18.9)	4302 (18.5)	
	Stage III	11167 (16.1)	6967 (15.2)	4200 (18.1)	
	Stage IV	3698 (5.3)	2257 (4.9)	1441 (6.2)	
	Missing n (%)	20346 (29.4)	13803 (30.1)	6543 (28.2)	
Country	Rwanda	26930 (38.9)	16651 (36.3)	10279 (44.2)	<0.001
	Burundi	9720 (14.1)	6409 (14.0)	3311 (14.2)	
	Cameroon	12482 (18.0)	8323 (18.1)	4159 (17.9)	
	DRC	3292 (4.8)	2718 (5.9)	574 (2.5)	
	ROC	16752 (24.2)	11832 (25.8)	4920 (21.2)	
Time Period	Year <= 2006	15054 (21.8)	10246 (22.3)	4808 (20.7)	<0.001
	Year 2007 - 2010	17488 (25.3)	11717 (25.5)	5771 (24.8)	
	Year 2011 - 2014	17761 (25.7)	12125 (26.4)	5636 (24.2)	
	Year >= 2015	18873 (27.3)	11845 (25.8)	7028 (30.2)	


ART Status at enrollment	Not on ART	32233 (46.6)	21357 (46.5)	10876 (46.8)	<0.001
	Before enrollment*	7601 (11.0)	5268 (11.5)	2333 (10.0)	
	Immediately after enrollment**	29342 (42.4)	19308 (42.0)	10034 (43.2)	

*: >30 days prior to enrollment day, ** within 30 days after enrollment day ¹ By Chi-Square Tests

Trends in measures of body mass index, CD4 cell count, and WHO stage at enrollment into care in all participating clinics

Figure 1 show calendar year trends in having a recent measure of body mass index (BMI), CD4 cell count and WHO staging at enrollment in the participating CA-leDEA site for patients in all participating countries and separately for each country. Overall, there was a steady increase in the proportion of patients with measures of BMI from 2004 to up to the period after 2017. There was a similar gradual increase in the proportion of patients with WHO staging from 2004-2007 before a gradual decrease from 2008 and a leveling off at 78% after 2017. A similar pattern emerged regarding availability of measures of CD4 cell count, which increased in all years, except in 2010 and 2014 when there were slight decreases and then a sharp decline in the period after 2017.

Fig. 1: Trends measures of BMI, CD4 cell count and WHO stage at enrollment in all countries participating in the CA-leDEA cohort



Disaggregated data of trends in measures of BMI, CD4 cell count and WHO staging by calendar years in each participating country are shown in supplementary figures S1-S5.

Starting with Burundi (Figure S1) where measures were only available to this study from 2009 on the proportion of patients with BMI and WHO Stage measures increased between 2009 and 2014 before a sharp decline for BMI and leveling off for WHO stage between 2015 and 2017, and slight decline in the period after 2017. Trends in available CD4 cell count measures were declined from 2009 and 2015, rose

1 slightly in 2016 when the Treat All guidelines ended the CD4 eligibility criterion for ART and thus
2 declined again from 2017 on. In Cameroon (Figure S2) trends in measures of BMI show a gradual
3 increase in the proportion of patients with this measure from 2004-2008, a gradual decrease until 2015
4 before a sharp increase since 2016. Trends in proportion of patients with measures of CD4 fluctuated
5 between 2004 and 2016 before a sharp decline since 2017. The proportion of patients with measure of
6 BMI was stable over time.

7
8 In the DRC, (Figure S3), trends in reported measures for BMI and WHO staging at enrollment in HIV care
9 was available for nearly all patients except in 2014 when measures were available for about 84% of
10 patients. Measures of CD4 cell count was available for at least 80% of patients until the year 2013 when
11 there was a sharp decline that culminated in less than 1% of patients with measures of CD4 reported
12 since 2017 when CD4 measures were no longer needed to determine eligibility for ART after 2016. In
13 ROC (Figure S4) availability of measures of CD4, WHO stage and BMI rose between 2004 and 2007. From
14 2008 the proportion of patients with these measures continued to fluctuate. Trends in the availability of
15 data for these measures tended upward since 2014 peaking at 83% for measures of BMI and CD4 and
16 45% for WHO stage.

17
18 Similar trends were observed in Rwanda (Figure S5) where the proportion of patients with measures of
19 CD4 cell count and WHO stage remained high (i.e. >70%) and stable over time before a downward slope
20 since 2016. The most significant decrease relates to the measure of CD4, which decreased to about one
21 third of the patients in the year 2017 and beyond, which coincided with the implementation of the Treat
22 All guidelines. Unlike measures of CD4 and WHO stage, measures of BMI, overall was available for less
23 than 50% of patients, but rose steadily through the years, peaking at 80% in 2017.

24
25 ***Characteristics of patients initiating ART within 30 days of enrolling in HIV care in the current***
26 ***in CA-leDEA clinic***

27 The characteristics of patients who first initiated ART within 30 days of enrollment in care at the
28 participating clinic are shown in table 2. Overall, 29,342 participants were initiated on ART within 30
29 days of their enrollment of whom 66% were women. Median age among this first time ART initiators
30 when they enrolled in care at the participating site was 35 years (IQR:29,43). Women were slightly
31 younger than men (34 years vs 39 years) ($p < .0.001$). Median CD4 among this first time ART initiators
32 within 30 days of enrollment was was 203 cell/uL (IQR: 100,340). Median CD4 cell count at ART initiation

1 was higher among women (216 cell/uL; IQR: 109, 356) than men (182 cell/uL; IQR: 82,309), $p < 0.001$.
 2 About 44% of first time ART initiators did so in the year 2015 and beyond. Overall, 36% and 20% of first
 3 time ART initiators were missing CD4 cell count and WHO staging measures.

4

5 **Table 2: Characteristics of patients initiating ART use within 30 days of enrollment into HIV care at**
 6 **participating CA-IeDEA clinic**

Variable	Code	Total	Women	Men	P-value
Adult		29342	19308 (65.8)	10034 (34.2)	
Pregnant			1700 (8.8)		
Age (yrs) median (IRQ)	Median (IQR)	35(29,43)	34(28,41)	39(32,45)	<0.001
	15-24	3402 (11.6)	2747 (14.2)	655 (6.5)	<0.001
	25-34	10324 (35.2)	7668 (39.7)	2656 (26.5)	
	35-44	9654 (32.9)	5700 (29.5)	3954 (39.4)	
	45+	5962 (20.3)	3193 (16.5)	2769 (27.6)	
Point of entry into care	PMTCT	2748 (9.4)	2479 (12.8)	269 (2.7)	<0.001
	TB	7 (0.0)	4 (0.0)	3 (0.0)	
	VCT	7219 (24.6)	3908 (20.2)	3311 (33.0)	
	Inpatient	434 (1.5)	209 (1.1)	225 (2.2)	
	Other	2342 (8.0)	1430 (7.4)	912 (9.1)	
	Unknown	16592 (56.5)	11278 (58.4)	5314 (53.0)	
Marital status	Single	8427 (28.7)	5710 (29.6)	2717 (27.1)	<0.001
	Married/in union	9388 (32.0)	5251 (27.2)	4137 (41.2)	
	Living with partner	2145 (7.3)	1535 (8.0)	610 (6.1)	
	Divorced	1538 (5.2)	1106 (5.7)	432 (4.3)	
	Widowed	2669 (9.1)	2273 (11.8)	396 (3.9)	
	Unknow/Missing	5175 (17.6)	3433 (17.8)	1742 (17.4)	
Weight for adults, Kg	Median (IQR)	58(50,65)	56(49,65)	60(53,68)	<0.001
	Missing n (%)	6254(21.3)	4224(21.9)	2030(20.2)	
Height for adults, CM	Median (IQR)	164(158,170)	160(156,165)	170(165,175)	<0.001
	Missing n (%)	4943(16.8)	3122(16.2)	1821(18.1)	
BMI	Median (IQR)	21.55(19.10,24.34)	21.91(19.27,24.89)	20.96(18.82,23.42)	<0.001
	Missing n (%)	9905(33.8)	6500(33.7)	3405(33.9)	
CD4 count (cells/uL)	Median (IQR)	203(100,340)	216(109,356)	182(82,309)	<0.001
	<100	4686 (16.0)	2863 (14.8)	1823 (18.2)	<0.001
	100-199	4575 (15.6)	2983 (15.4)	1592 (15.9)	
	200-349	5160 (17.6)	3457 (17.9)	1703 (17.0)	
	>350	4418 (15.1)	3259 (16.9)	1159 (11.6)	
	Missing	10503 (35.8)	6746 (34.9)	3757 (37.4)	
WHO Stage at enrollment	Stage I	9171 (31.3)	6160 (31.9)	3011 (30.0)	<0.001
	Stage II	6348 (21.6)	4184 (21.7)	2164 (21.6)	
	Stage III	6021 (20.5)	3721 (19.3)	2300 (22.9)	
	Stage IV	1935 (6.6)	1180 (6.1)	755 (7.5)	
	Missing	5867 (20.0)	4063 (21.0)	1804 (18.0)	
Country	Rwanda	9091 (31.0)	5289 (27.4)	3802 (37.9)	<0.001
	Burundi	3900 (13.3)	2671 (13.8)	1229 (12.2)	

	Cameroon	9371 (31.9)	6148 (31.8)	3223 (32.1)	
	DRC	1046 (3.6)	847 (4.4)	199 (2.0)	
	ROC	5934 (20.2)	4353 (22.5)	1581 (15.8)	
Time Period	Year <= 2006	3540 (12.1)	2343 (12.1)	1197 (11.9)	<0.001
	Year 2007 - 2010	5395 (18.4)	3643 (18.9)	1752 (17.5)	
	Year 2011 - 2014	7618 (26.0)	5432 (28.1)	2186 (21.8)	
	Year >= 2015	12789 (43.6)	7890 (40.9)	4899 (48.8)	

* from 30 days prior to enrollment to 30 days after enrollment. ¹By Chi-Square Test

Characteristics of patients already using ART prior to enrollment in HIV care at participating

CA-IeDEA clinic

Table 3 shows the characteristics of 7,601 patients who were already using ART prior to enrolling in HIV care in the current CA-IeDEA clinic. Presumably, these were patients transferring from a previous site where they were already initiated on ART after HIV diagnosis. Women made up about two-thirds (69%) of patients. Median age among ART experienced users was 36 years (IQR:30,43) and women were younger (35 years, IQR: 29, 41) than men (40 years IQR: 33, 47) ($p < 0.001$). Voluntary Counseling and Testing (38%) and PMTCT (11%) were the main sources of entry into care for ART experienced patients. ART experienced women had higher median CD4 cell/uL than men 392 (IQR 232,584) than ART experienced men 293 (IQR 160, 454). About 61% of experienced ART users were initiated on ART prior to 2015.

1 **Table 3: Characteristics of patients using ART prior to enrollment in HIV care at participating CA-IeDEA**
 2 **clinic**

Variable	Code	Total	Women	Men	P-value
Adult		7601	5268 (69.3)	2333 (30.7)	
Pregnant			193 (3.7)		
Age (yrs) median (IQR)	Median (IQR)	36(30,43)	35(29,41)	40(33,47)	<0.001
	15-24	750 (9.9)	600 (11.4)	150 (6.4)	<0.001
	25-34	2568 (33.8)	2029 (38.5)	539 (23.1)	
	35-44	2605 (34.3)	1736 (33.0)	869 (37.2)	
	45+	1678 (22.1)	903 (17.1)	775 (33.2)	
Point of entry into care	PMTCT	840 (11.1)	737 (14.0)	103 (4.4)	<0.001
	VCT	2903 (38.2)	1868 (35.5)	1035 (44.4)	
	Inpatient	98 (1.3)	53 (1.0)	45 (1.9)	
	Other	716 (9.4)	502 (9.5)	214 (9.2)	
	Unknown	3044 (40.0)	2108 (40.0)	936 (40.1)	
Marital status	Single	1174 (15.4)	836 (15.9)	338 (14.5)	<0.001
	Married/in union	1588 (20.9)	898 (17.0)	690 (29.6)	
	Living with partner	374 (4.9)	271 (5.1)	103 (4.4)	
	Divorced	339 (4.5)	283 (5.4)	56 (2.4)	
	Widowed	650 (8.6)	580 (11.0)	70 (3.0)	
	Unknow/Missing	3476 (45.7)	2400 (45.6)	1076 (46.1)	
Weight for adults, Kg	Median (IQR)	59(52,67)	58(51,66)	60(54,67)	<0.001
	Missing n (%)	1228(16.2)	833(15.8)	395(16.9)	
Height for adults, CM	Median (IQR)	162(157,169)	160(155,165)	170(165,175)	<0.001
	Missing n (%)	1311(17.2)	867(16.5)	444(19.0)	
BMI	Median (IQR)	22.22(19.92,24.97)	22.83(20.31,25.71)	21.11(19.27,23.37)	<0.001
	Missing n (%)	2379(31.3)	1603(30.4)	776(33.3)	
CD4 count (cells/uL)	Median (IQR)	361(205,543)	392(232,584)	293(160,454)	<0.001
	<100	549 (7.2)	323 (6.1)	226 (9.7)	<0.001
	100-199	684 (9.0)	414 (7.9)	270 (11.6)	
	200-349	1241 (16.3)	827 (15.7)	414 (17.7)	
	>350	2653 (34.9)	2030 (38.5)	623 (26.7)	
	Missing	2474 (32.5)	1674 (31.8)	800 (34.3)	
WHO Stage at enrollment	Stage I	2064 (27.2)	1508 (28.6)	556 (23.8)	<0.001
	Stage II	1238 (16.3)	867 (16.5)	371 (15.9)	
	Stage III	1650 (21.7)	1104 (21.0)	546 (23.4)	
	Stage IV	465 (6.1)	278 (5.3)	187 (8.0)	
	Missing	2184 (28.7)	1511 (28.7)	673 (28.8)	
Country	Rwanda	5159 (67.9)	3492 (66.3)	1667 (71.5)	<0.001
	Burundi	290 (3.8)	238 (4.5)	52 (2.2)	
	Cameroon	1849 (24.3)	1317 (25.0)	532 (22.8)	
	DRC	165 (2.2)	121 (2.3)	44 (1.9)	
	ROC	138 (1.8)	100 (1.9)	38 (1.6)	
Time Period	Year <= 2006	484 (6.4)	326 (6.2)	158 (6.8)	<0.001
	Year 2007 - 2010	1603 (21.1)	1036 (19.7)	567 (24.3)	
	Year 2011 - 2014	2566 (33.8)	1854 (35.2)	712 (30.5)	
	Year >= 2015	2948 (38.8)	2052 (39.0)	896 (38.4)	


1 * more than 30 days prior to enrollment ¹ By Chi-Square test

2
3
4 ***Trends in measures of CD4 cell count and ART use prior to and after enrollment into care in CA- leDEA***

5 Before the WHO's 2015 Treat All recommendations, CD4 cell count was an important criterion for
6 determining eligibility for ART initiation. While CD4 testing is no longer required for determining
7 eligibility for ART, pre-treatment CD4 testing is still recommended in order to identify patients with
8 advanced disease who are at elevated risk for mortality. We examined trends in median CD4 cell count
9 among all patients enrolling in HIV care at the participating clinics as well as ART use either prior to or
10 after they enrolled in HIV care at the current site.

11
12 Among patients at participating CA-leDEA sites, median CD4 cell count for all patients when they
13 enrolled in care increased from 190 cells/uL in the period before 2005 to 334 cells/uL after 2017 (Figure
14 2). In 2005, the proportion of respondents who were already using ART before they enrolled in HIV care
15 at the current CA-leDEA participating site was less than 2% increasing to 18% in 2017. The proportion of
16 patients who initiated ART within 30 days of enrollment in HIV care at the current CA-leDEA site grew
17 from 16% in 2005 to 75% after 2017.

18
19 **Fig. 2: Trends in CD4 cell count and ART use before enrollment and after enrollment in HIV care**
20 **among PLWH in all participating CA-leDEA countries**



21
22
23 Disaggregated data by country is presented in Supplemental Figures S6-S10. In Burundi (Figure S6),
24 recent median CD4 cell count at enrollment increased from 281 cells /uL in 2009 to 504 cells/uL in 2017
25 before a sharp decline to 372 cells/uL after 2017. About 5% of patients enrolling in HIV care at the
26 participating CA-leDEA site were already using ART before enrollment, but among those newly initiating
27 ART, the proportion rose from about 10% in 2009 to 91% after 2017.

1
2 The trend in Cameroon (Figure S7) show median CD4 increase from 155 cells/uL in 2004 to 229 cells/uL
3 in 2017 and falling to 177 cells/uL after 2017. The proportion of patients using ART prior to enrollment
4 into CA-IeDEA participating clinic increased from 8% in 2004 to 22% in the period after 2017 while the
5 proportion of patients initiating ART the first time when they enrolled in the CA-IeDEA participating site
6 increased from 67% in 2004 to 74% after 2017.

7
8 In the DRC (Figure S8), median CD4 fluctuated from 327 cells/uL in 2005 to 295 cells/uL in 2006 and 375
9 cells/uL in 2007. Median CD4 cell count was highest in 2017 at 517 cells/uL. Similar fluctuations were
10 observed with regard to ART use either prior to or after enrollment in HIV care at the participating clinic.

11
12 In the ROC (Figure S9), median CD 4 cell count among those enrolled in care fell from 221 cells/uL in the
13 period prior to 2005 to as low as 142 cells/uL in 2005 before rising between 2006 and 2010 and then
14 slightly from 2011 until 2015 and from 2016 onwards. Between 2005 and 2009, less than 4% of patients
15 who enrolled in HIV at the current site were experienced ART users while the proportion of first-time
16 users increased from 4% in 2005 to 51% in 2007 and again from 2010 onwards.

17
18 Trends in Rwanda were similar to those observed in the other countries (Figure S10). Recent median
19 CD4 at enrollment increased in 2005 and then fell in 2006 before rising again and peaking at 457 cells/uL
20 after 2017. The proportion of patients who were experienced ART users prior to enrollment was 2% in
21 2005 and 26% after 2017. The proportion of first time ART initiators increased 32% in 2005 to 67% after
22 2017.

23 24 **Discussion**

25 In this study describing trends in demographic, clinical and immunological characteristics of the largest
26 cohort of adult PLWH entering care and initiating ART in Central Africa from 2004-2018, we found
27 increases in baseline CD4 cell count among patients enrolling in HIV care in the participating CA-IeDEA
28 sites and in the proportion of first time ART users within 30 days of entry into care at participating sites
29 in Burundi, Cameroon, DRC, ROC and Rwanda.

30
31 These findings shed light on important demographic, clinical and immunological characteristics of
32 patients entering HIV care and those initiating ART, and also highlight the progress and challenges in

1 early HIV diagnosis, and ART initiation that are critical to the universal goal to eliminate the virus by
2 2030. More importantly, our findings can inform effective programs and/or policies to improve long
3 term outcomes and quality of life and substantially reduce mortality among PLWH living in Central
4 Africa, particularly in the era of universal ART use.¹¹

5
6 Women comprised most of patients who enrolled in care and initiated ART within 30 days of enrollment
7 in our CA-leDEA cohort. While other studies^{12, 13} reported that HIV prevalence in SSA is higher among
8 women than men, this discrepancy may reflect the fact that women were more likely to be tested for
9 HIV earlier than men because of contacts with antenatal care during pregnancy.¹³ The higher proportion
10 of women represented in the CA-leDEA cohort may partly reflect disparities in testing, but may also
11 reflect gender disparities and higher risk of transmission in women and perhaps, higher mortality rates
12 in men.¹⁴

13
14 Before the WHO's 2015 recommendation of universal HIV treatment for all PLWH, also known as "Treat
15 All", CD4 cell count, and WHO staging were the most commonly used criteria for determining treatment
16 eligibility.¹⁵ Our findings suggest that at that time information on CD4 cell count and WHO staging was
17 missing for a substantial proportion of patients, with likely implications for delayed timing of ART
18 initiation. While there were differences between countries and between women and men, the low
19 median CD4 cell counts at entry into care in the participating CA-leDEA site suggests that PLWH were
20 being diagnosed late and that they were likely entering care with advanced disease, particularly in the
21 pre-Treat All era. In the post Treat All era, rising median CD4 cell counts suggests that patients were
22 entering HIV care earlier, although it is worth highlighting that even after CD4 eligibility thresholds were
23 eliminated, median CD4 cell count at entry into care remained less than 500 cells/uL. We also observed
24 sex differences across countries with women having higher CD4 cell count at enrollment into HIV care at
25 the participating CA-leDEA site and ART initiation than men, perhaps reflecting women's earlier access
26 to HIV testing and diagnosis through antenatal care in PMTCT clinics.

27
28 Additionally, the fact that median CD4 count was quite low in the pre-treat all era suggests that patients
29 may not have been accessing treatment early enough and may have been severely immune-
30 compromised by the time treatment is initiated. Analysis of median CD4 count by country shows that
31 patients in Rwanda had the highest median CD4 cell count when they enrolled in care in our
32 participating clinics, which is higher than patients in Burundi, Cameroon, DR Congo and ROC.

1 Over the time period focused on in this study, there were changes in recommended criteria for ART
2 initiation among PLWH, especially more recently, the Treat All guidelines that recommended immediate
3 ART initiation upon HIV diagnosis regardless of clinical and immunological parameters.¹⁶ Arguably,
4 changes in treatment guidelines may have contributed to the increased proportion of those initiating
5 immediate ART use after entry into care at the participating clinics. Our findings show that ART initiation
6 increased dramatically for PLWH enrolled from 2015 onwards, coinciding with the
7 existence/implementation of the Treat All guidelines.

8
9 HIV Voluntary counseling and testing (HIV-VCT) is an important gateway to knowing one's HIV status.
10 VCT is beneficial for the individual by ensuring they know their HIV status and are able to take
11 preventive actions against HIV acquisition or transmission to others. Additionally, knowledge of HIV
12 seropositive status increases the likelihood of early engagement in care, facilitates timely ART initiation
13 and confer protective benefits on the entire population.¹⁷ Consistent with evidence from other studies¹⁸,
14 we found VCT clinics as an important route of entry into HIV care for a large proportion of patients in
15 our cohort and this may have contributed to the rapid initiation of ART within 30 days of enrollment.

16
17 This descriptive study utilized data from 5 countries to describe the demographic, clinical and
18 immunological characteristics of PLWH in Burundi, Cameroon, Democratic Republic of Congo, Republic
19 of Congo and Rwanda. This combined data set that examined trends in demographic, clinical and
20 immunological characteristics over a 14-year period in the largest cohort of adult PLWH entering care
21 and initiating ART in Central Africa is a strength of the study. Nonetheless, there are limitations, which
22 warrant caution in interpretation of the findings reported here. First, we highlight the different sample
23 sizes of the cohort in each participating country. That nearly 4 in 10 CA-leDEA patients were from
24 Rwanda may have skewed the results described here. Second, missing data on weight, height, CD4 cell
25 count and WHO staging in many clinics impacted the findings reported in this study. Additionally, the
26 potential non-representativeness of the selected clinics and their concentration in largely urban and
27 peri-urban settings is another limitation as clinics in urban and semi-urban settings do not necessarily
28 represent all health facilities, especially those in rural settings providing HIV care in all countries. In
29 addition, the participating clinics may be better resourced to scale up patient enrollment in care and
30 treatment initiation, which may not reflect the disparity between urban/peri-urban and rural health
31 facilities.

32

1 Despite these limitations, the CA-IeDEA as a cohort study offers an opportunity for further longitudinal
2 analysis of the socio-contextual and health system factors that facilitate or hinder timely HIV diagnosis,
3 enrollment in care, ART initiation among PLWH in the region. This is critical because Central Africa
4 continues to lag behind other regions in curtailing the spread of HIV. For example, in-depth analyses are
5 needed to examine trends in long-term outcomes among PLWH in this region so as to generate evidence
6 to inform programs and policies that addresses the circumstances that are unique to each country and
7 the region.

8

9 **Conclusion**

10 Trends in demographic, clinical and immunological characteristics of patients entering into HIV care and
11 subsequently initiating ART in the participating sites in Burundi, Cameroon, DRC, ROC and Rwanda
12 highlight improvements over time among those accessing care in this cohort. Although progress is being
13 made especially with improvements in CD4 cell count and the number of patients initiating ART soon
14 after enrolling in care, gaps still remain with scaling up access to care for PLWH who may not be
15 accessing care. Thus, implementing contextually relevant program and policy strategies to address gaps
16 that remain is critical.

17

1 **References**

- 2 1. Joint United Nations Program on AIDS: Global HIV/AIDS Statistics 2019 Fact Sheet. Available at
3 <https://www.unaids.org/en/resources/fact-sheet>
4
- 5 2. World Health Organization. Consolidated guidelines on the use of Antiretroviral Therapy drugs
6 for treating and preventing HIV infection. Recommendations for a public health approach.
7 Second Edition June 2016. Available at <https://www.who.int/hiv/pub/arv/arv-2016/en/>
8
- 9 3. Joint United Nations Program on AIDS. West and Central Africa Regional Report. Available at
10 <https://www.unaids.org/en/regionscountries/westandcentralafrica>
11
- 12 4. Joint United Nations Program on AIDS: 90-90-90 Treatment for All. Available at
13 <https://www.unaids.org/en/resources/909090>
14
- 15 5. Joint United Nations Program on AIDS. UNAIDS Data 2018. Available at
16 https://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf
17
- 18 6. Joint United Nations Program on AIDS. The Western and Central Africa catch up plan: Putting
19 HIV Treatment on the fast track by 2018. Available at
20 https://www.unaids.org/sites/default/files/media_asset/WCA-catch-up-plan_en.pdf
21
- 22 7. Joint United Nations Program on AIDS. Ending AIDS: Progress toward the 90-90-90 targets.
23 Available at
24 https://www.unaids.org/en/resources/documents/2017/20170720_Global_AIDS_update_2017
25
- 26 8. Kharsany AB, Karim QA. HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges
27 and Opportunities. *Open AIDS J.* 2016;10:34–48. Published 2016 Apr 8.
28 doi:10.2174/1874613601610010034
29
- 30 9. Egger M, Ekouevi DK, Williams C, et al. Cohort Profile: the international epidemiological
31 databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. *Int J Epidemiol.* 2012;41(5):1256–
32 1264. doi:10.1093/ije/dyr080
33
- 34 10. Project RedCap. Available at <https://projectredcap.org/about/>
35
- 36 11. Gakhar H, Kamali A, Holodniy M. Health-related quality of life assessment after antiretroviral
37 therapy: a review of the literature. *Drugs.* 2013;73(7):651–672. doi:10.1007/s40265-013-0040-4
38
- 39 12. Hegdahl HK, Fylkesnes KM, Sandøy IF. Sex Differences in HIV Prevalence Persist over Time:
40 Evidence from 18 Countries in Sub-Saharan Africa. *PLoS One.* 2016;11(2):e0148502. Published
41 2016 Feb 3. doi:10.1371/journal.pone.0148502
42
- 43 13. Sharma M, Barnabas RV, Celum C. Community-based strategies to strengthen men's
44 engagement in the HIV care cascade in sub-Saharan Africa. *PLoS Med.* 2017;14(4):e1002262.
45 Published 2017 Apr 11. doi:10.1371/journal.pmed.1002262
46

1 14. Hegdahl HK, Fylkesnes KM, Sandøy IF. Sex Differences in HIV Prevalence Persist over Time:
2 Evidence from 18 Countries in Sub-Saharan Africa. *PLoS One*. 2016;11(2):e0148502. Published
3 2016 Feb 3. doi:10.1371/journal.pone.0148502
4
5 15. Ford N, Meintjes G, Vitoria M, Greene G, Chiller T. The evolving role of CD4 cell counts in HIV
6 care. *Curr Opin HIV AIDS*. 2017;12(2):123–128. doi:10.1097/COH.0000000000000348
7
8 16. World Health Organization. Treat all policy adoption and implementation in all countries.
9 Available at <https://www.who.int/hiv/pub/arv/treat-all-uptake/en/>
10
11 17. World Health Organization. Scaling up HIV testing and counseling services. A toolkit for
12 managers. Available at <https://www.who.int/hiv/pub/vct/counsellingtestingtoolkit.pdf>
13
14 18. Fonner VA, Denison J, Kennedy CE, O'Reilly K, Sweat M. Voluntary counseling and testing (VCT)
15 for changing HIV-related risk behavior in developing countries. *Cochrane Database Syst Rev*.
16 2012;9(9):CD001224. Published 2012 Sep 12. doi:10.1002/14651858.CD001224.pub4
17
18
19

1 **Funding acknowledgement**

2 Research reported in this publication was supported by the National Institutes of Health's National
3 Institute of Allergy and Infectious Diseases (NIAID), the *Eunice Kennedy Shriver* National Institute of Child
4 Health & Human Development (NICHD), the National Cancer Institute (NCI), the National Institute on
5 Drug Abuse (NIDA), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on
6 Alcohol Abuse and Alcoholism (NIAAA), the National Institute of Diabetes and Digestive and Kidney
7 Diseases (NIDDK), the Fogarty International Center (FIC), the National Library of Medicine (NLM), and
8 the Office of the Director (OD) under Award Number U01AI096299 (Central Africa-leDEA). The content is
9 solely the responsibility of the authors and does not necessarily represent the official views of the
10 National Institutes of Health.

11 **Acknowledgements list**

12 **Site investigators and cohorts:**

13
14 Nimbona Pélagie, Association Nationale de Soutien aux Séropositifs et Malade du Sida (ANSS), Burundi;
15 Patrick Gateretse, Jeanine Munezero, Valentin Nitereka, Théodore Niyongabo, Christelle Twizere, Centre
16 National de Reference en Matière de VIH/SIDA, Burundi; Hélène Bukuru, Thierry Nahimana, Centre
17 Hospitalo-Universitaire de Kamenge (CHUK), Burundi; Elysée Baransaka, Patrice Barasukana, Eugene
18 Kabanda, Martin Manirakiza, François Ndikumwenayo, CHUK/Burundi National University, Burundi;
19 Jérémie Biziragusenyuka, Ange Marie Michelline Munezero, Hospital Prince Régent Charles (HPRC),
20 Burundi; Tabeyang Mbuh, Kinge Thompson Njje, Edmond Tchasse, Kien-Atsu Tsi, Bamenda Hospital,
21 Cameroon; Rogers Ajeh, Mark Benwi, Marc Lionel Ngamani, Victorine Nkome, Falone Sandjong, Clinical
22 Research Education and Consultancy (CRENC), Cameroon; Anastase Dzudie, CRENC and Douala General
23 Hospital, Cameroon; Akindeh Mbuh, CRENC and University of Yaoundé, Cameroon; Djenabou Amadou,
24 Amadou Dodo Balkissou, Eric Ngassam, Eric Walter Pefura Yone, Jamot Hospital, Cameroon; Alice
25 Ndelle Ewanoge, Norbert Fuhngwa, Ernestine Kendowo, Chris Moki, Denis Nsame Nforniwe, Limbe
26 Regional Hospital, Cameroon; Catherine Akele, Faustin Kitetele, Patricia Lelo, Martine Tabala,
27 Kalembelembe Pediatric Hospital, Democratic Republic of Congo; Emile Wemakoy Okitolonda, Cherubin
28 Ekembe, Kinshasa School of Public Health, Democratic Republic of Congo; Merlin Diafouka, Martin
29 Herbas Ekati, Dominique Mahambou Nsonde, CTA Brazzaville, Republic of Congo; Adolphe Mafou, CTA
30 Pointe-Noire, Republic of Congo; Nicole Ayinkamiye, Jules Igirimbabazi, Bethsaida Health Center,
31 Rwanda; Emmanuel Ndamijimana, Providance Uwizeza, Busanza Health Center, Rwanda; Emmanuel
32 Habarurema, Marie Luise Nyiraneza, Gahanga Health Center, Rwanda; Dorothee Mukamusana, Liliane
33 Tuyisenge, Gikondo Health Center, Rwanda; Catherine Kankindi, Christian Shyaka, Kabuga Health Center,
34 Rwanda; Marie Grace Ingabire, Bonheur Uwakijjwe, Kicukiro Health Center, Rwanda; Jules Ndumuhire,
35 Marie Goretti Nyirabahutu, Masaka Health Center, Rwanda; Yvette Ndoli, Oliver Uwamahoro,
36 Nyarugunga Health Center, Rwanda; Ribakare Muhayimpundu, Sabin Nsanzimana, Eric Remera,
37 Esperance Umumararungu, Rwanda Biomedical Center, Rwanda; Lydia Busingye, Alex M Butera,
38 Josephine Gasana, Thierry Habiryayo, Charles Ingabire, Jules Kabahizi, Jean Chrysostome Kagimbana,
39 Faustin Kanyabwisha, Gallican Kubwimana, Benjamin Muhoza, Athanase Munyaneza, Gad Murenzi,
40 Françoise Musabyimana, Francine Mwiza, Gallican Nshogoza Rwibasira, Jean d'Amour Sinayobye, Patrick
41 Tuyisenge, Rwanda Military Hospital, Rwanda; Chantal Benekigeri, Jacqueline Musaninyange, WE-ACTx
42 Health Center, Rwanda.

43 **Coordinating and Data Centers:**

44 Adebola Adedimeji, Kathryn Anastos, Madeline Dilorenzo, Lynn Murchison, Jonathan Ross, Marcel
45 Yotebieng, Albert Einstein College of Medicine, USA; Diane Addison, Ellen Brazier, Heidi Jones, Elizabeth
46 Kelvin, Sarah Kulkarni, Denis Nash, Matthew Romo, Olga Tymejczyk, Institute for Implementation
47 Science in Population Health, Graduate School of Public Health and Health Policy, City University of New
48


1 York (CUNY), USA; Batya Elul, Columbia University, USA; Xiatao Cai, Allan Dong, Don Hoover, Hae-Young
2 Kim, Chunshan Li, Qiuhi Shi, Data Solutions, USA; Robert Agler, Kathryn Lancaster, The Ohio State
3 University, USA; Mark Kuniholm, University at Albany, State University of New York, USA; Andrew
4 Edmonds, Angela Parcesepe, Jess Edwards, University of North Carolina at Chapel Hill, USA; Olivia Keiser,
5 University of Geneva; Stephany Duda; Vanderbilt University School of Medicine, USA; April Kimmel,
6 Virginia Commonwealth University School of Medicine, USA.

7
8

1 **Supplementary Materials**

2

3 **Figure. S1: Trends in proportions having a recent measure for BMI, CD4 cell count and WHO stage in**
 4 **the Burundi CA-leDEA cohort**




5

6

7 **Figure. S2: Trends in proportions having a recent measure for BMI, CD4 cell count and WHO stage in**
 8 **the Cameroon CA-leDEA cohort**

9




10

11

12 **Figure S3: Trends in proportions having a recent measure for BMI, CD4 cell count and WHO stage in**
 13 **the DRC CA-leDEA cohort**

14




15


16

17


1 **Fig. S4: Trends in proportions having a recent measure for BMI, CD4 cell count and WHO stage in the**
 2 **ROC CA-leDEA cohort**




3
 4
 5 **Fig. S5: Trends in having a recent measure for BMI, CD4 cell count and WHO stage at enrollment in**
 6 **HIV care in the Rwanda CA-leDEA cohort**



7
 8
 9 **Fig. S6: Trends in CD4 cell count and ART use before enrollment and after enrollment in HIV care**
 10 **among PLWH in Burundi CA-leDEA cohort**




11
 12
 13
 14
 15 **Fig. S7: Trends in CD4 cell count and ART use before enrollment and after enrollment in HIV care**
 16 **among PLWH in Cameroon CA-leDEA cohort**




1
2
3
4
5

Fig. S8: Trends in CD4 cell count and ART use before enrollment and after enrollment in HIV care among PLWH in DRC CA-leDEA cohort




6
7
8
9

Fig. S9: Trends in CD4 cell count and ART use before enrollment and after enrollment in HIV care among PLWH in ROC CA-leDEA cohort



10
11
12

1 **Fig. S10: Trends in CD4 cell count and ART use before enrollment and after enrollment in HIV care**
2 **among PLWH in Rwanda CA-leDEA cohort**



3
4
5
6
7
8